Sinomenine exerts cardioprotective effects in a rat model of myocardial ischemia/reperfusion injury

Abstract

Objective: To evaluate the cardioprotective effects of sinomenine using the ischemia/reperfusion (I/R) rat model.

Methods: Wistar rats were randomly divided into 6 groups: group I with reperfusion, group II perfused with sinomenine, group III perfused with 5-hydroxydecanoate (5-HD), group IV perfused with 5-HD+sinomenine, group V perfused with L-nitro arginine methyl ester (L-NAME), group VI perfused with L-NAME+sinomenine. Myocardial ischemia was induced by interrupting the aortic blood supply for 30 min, followed by reperfusion (55 min). Cardiac, hepatic, antioxidant, and inflammatory parameters were assessed. Additionally, endothelin, tissue factor, platelet-activating factor, plasminogen activator inhibitor, plasma fibrinogen, and thromboxane B2 were also analyzed.

Results: Administration of 5-HD or L-NAME, used as the selective antagonist of mitoKATP and NO system, respectively, resulted in significantly increased levels of premature ventricular complexes, lactate dehydrogenase, ventricular fibrillation, ventricular tachycardia, and arrhythmia intensity (P<0.05). In contrast, sinomenine significantly reduced the level of troponin I, lactate dehydrogenase, creatine kinase, and creatine kinase MB compared to the 5-HD group and the L-NAME group (P<0.05). Additionally, sinomenine significantly reduced malondialdehyde level and enhanced the levels of superoxide dismutase, glutathione peroxidase, catalase, and glutathione/glutathione disulfide ratio (P<0.05). It also significantly suppressed the levels of endothelin-1, platelet-activating factor, tissue factor, plasminogen activator inhibitor 1, thromboxane B2, and plasma fibrinogen (P<0.05).

Conclusions: These results suggest that sinomenine exhibits significant cardioprotection effects against I/R-induced cardiac injury in rats.

Keywords

Sinomenine / Arrhythmia / Ischemia reperfusion / Mitochondrial KATP channel / Myocardial infarction / Thrombosis

Conflict of interest statement

The authors declare that there is no conflict of interest.

Funding

The authors received no extramural funding for this study.

Data availability statement

The data supporting the findings of this study are available from the corresponding author upon request.

Authors’ contributions

MNS conducted the conceptualization, methodology, and drafted the manuscript. BBF, YTZ, ML, AK, and KY participated in animal experiments. ZG contributed to the conception and design of the study. All authors have read and approved the final manuscript.

Publisher’s note

The Publisher of the Journal remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

[1] Xing M, Jiang Y, Bi W, Gao L, Zhou YL, Rao SL, et al. Strontium ions protect hearts against myocardial ischemia/reperfusion injury. Sci Adv 2021; 7(3). doi: 10.1126/sciadv.abe0726.

[2] Sun X, Chen H, Gao R, Qu Y, Huang Y, Zhang N, et al. Intravenous transplantation of an ischemic-specific peptide-TPP-mitochondrial compound alleviates myocardial ischemic reperfusion injury. ACS Nano 2023; 17(2):896-909.

[3] Wei Y, Zhu M, Li S, Hong T, Guo X, Li Y, et al. Engineered biomimetic nanoplatform protects the myocardium against ischemia/reperfusion injury by inhibiting pyroptosis. ACS Appl Mater Interfaces 2021; 13(29):33756-33766.

[4] Lin JH, Yang KT, Lee WS, Ting PC, Luo YP, Lin DJ, et al. Xanthohumol protects the rat myocardium against ischemia/reperfusion injury-induced ferroptosis. Oxid Med Cell Longev 2022;2022. doi: 10.1155/2022/9523491.

[5] Wang G. Aerobic exercise ameliorates myocardial ischemia/reperfusion injury and thrombosis of diabetic rats via activation of AMPK/Sirt1/PGC-1α pathway. Gen Physiol Biophys 2022; 41(4):319-328.

[6] Feng MH, Li ZX, Wang Q, Manyande A, Li YJ, Li SY, et al. Neurochemical alterations of different cerebral regions in rats with myocardial ischemia-reperfusion injury based on proton nuclear magnetic spectroscopy analysis. Aging 2021; 13(2):2294-2309.

[7] Huang Y, Zhou B. Mitochondrial dysfunction in cardiac diseases and therapeutic strategies. Biomedicines 2023; 11(5). doi: 10.3390/biomedicines11051500.

[8] Carinci M, Vezzani B, Patergnani S, Ludewig P, Lessmann K, Magnus T, et al. Different roles of mitochondria in cell death and inflammation: Focusing on mitochondrial quality control in ischemic stroke and reperfusion. Biomedicines 2021; 9(2):1-28.

[9] Lu J, Meng Y, Wang R, Zhang R. Anti-arrhythmogenic effects of quercetin postconditioning in myocardial ischemia/reperfusion injury in a rat model. J King Saud Univ Sci 2020; 32(3):1910-1916.

[10] Chen Y, Chen H, Chen Y, Yang Z, Zhou T, Xu W. Dexmedetomidine preconditioning attenuates myocardial ischemia/ reperfusion injury in rats by suppressing mitophagy via activating A₂-adrenergic receptor. Arq Bras Cardiol 2023; 120(10). doi: 10.36660/abc.20220750.

[11] Tiwari AK, Gupta PS, Prasad M, Malairajan P. Modulation of Inula racemosa Hook extract on cardioprotection by ischemic preconditioning in hyperlipidaemic rats. J Pharmacopuncture 2022; 25(4):369-381.

[12] El-Marasy SA, El Awdan SA, Hassan A, Abdallah HMI. Cardioprotective effect of thymol against adrenaline-induced myocardial injury in rats. Heliyon 2020; 6(7). doi: 10.1016/j.heliyon.2020.e04431.

[13] Li Y, Xie H, Zhang H. Protective effect of sinomenine against inflammation and oxidative stress in gestational diabetes mellitus in female rats via TLR4/MyD88/NF-κB signaling pathway. J Food Biochem 2021; 45(11). doi: 10.1111/jfbc.13952.

[14] Lu C, Guo X, He X, Chang Y, Zheng F, Xu C, et al. Cardioprotective effects of sinomenine in myocardial ischemia/reperfusion injury in a rat model. Saudi Pharm J 2022; 30(6):669-678.

[15] Brauer M, Roth GA, Aravkin AY, Zheng P, Abate KH, Abate YH, et al. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: A systematic analysis for the Global Burden of Disease Study 2021. Lancet 2024; 403(10440):2162-2203.

[16] Hong H, Lu X, Lu Q, Huang C, Cui Z. Potential therapeutic effects and pharmacological evidence of sinomenine in central nervous system disorders. Front Pharmacol 2022; 13. doi: 10.3389/fphar.2022.1015035.

[17] Zhang MW, Wang XH, Shi J, Yu JG. Sinomenine in cardio-cerebrovascular diseases: Potential therapeutic effects and pharmacological evidences. Front Cardiovasc Med 2021; 8. doi: 10.3389/fcvm.2021.749113.

[18] Liu Y, Song Y, Li S, Mo L. Cardioprotective effect of quercetin against ischemia/reperfusion injury is mediated through NO system and mitochondrial K-ATP channels. Cell J 2021; 23(2):184-190.

[19] Sharma M, Pal P, Pottoo FH, Kumar S. Mechanistic role of methanolic extract of Taraxacum officinale roots as cardioprotective against ischemia-reperfusion injury-induced myocardial infarction in rats. Appl Biotechnol Biochem 2023; 195(5):3384-3405.

[20] Xiao Y, Chen W, Zhong Z, Ding L, Bai H, Chen H, et al. Electroacupuncture preconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting mitophagy mediated by the mTORC1-ULK1-FUNDC 1 pathway. Biome Pharmacother 2020;127. doi: 10.1016/j.biopha.2020.110148.

[21] Cheng XF, He ST, Zhong GQ, Meng JJ, Wang M, Bi Q, et al. Exosomal HSP90 induced by remote ischemic preconditioning alleviates myocardial ischemia/reperfusion injury by inhibiting complement activation and inflammation. BMC Cardiovasc Disord 2023; 23(1). doi: 10.1186/s12872-023-03043-y.

[22] He H, Mulhern RM, Oldham WM, Xiao W, Lin YD, Liao R, et al. L-2-hydroxyglutarate protects against cardiac injury via metabolic remodeling. Circ Res 2022; 131(7):562-579.

[23] Bhatt PC, Pathak S, Kumar V, Panda BP. Attenuation of neurobehavioral and neurochemical abnormalities in animal model of cognitive deficits of Alzheimer’s disease by fermented soybean nanonutraceutical. Inflammopharmacology 2018; 26(1):105-118.

[24] Wang Q, Ju F, Li J, Liu T, Zuo Y, Abbott GW, et al. Empagliflozin protects against renal ischemia/reperfusion injury in mice. Sci Rep 2022; 12(1). doi: 10.1038/s41598-022-24103-x.

[25] Zhang Q, Peng Y, Liu J, Yang Y, Hu Z, Zhou Y, et al. 7-Hydroxyflavone alleviates myocardial ischemia/reperfusion injury in rats by regulating inflammation. Molecules 2022; 27(17). doi: 10.3390/molecules27175371.

[26] Huang D, Ju F, Du L, Liu T, Zuo Y, Abbott GW, et al. Empagliflozin protects against pulmonary ischemia/reperfusion injury via an extracellular signal-regulated kinases 1 and 2-dependent mechanism. J Pharmacol Exp Ther 2022; 380(3):230-241.

[27] Tappia PS, Shah AK, Ramjiawan B, Dhalla NS. Modification of ischemia/reperfusion-induced alterations in subcellular organelles by ischemic preconditioning. Int J Mol Sci 2022; 23(7). doi: 10.3390/ijms23073425.

[28] Li Y, Hao H, Yu H, Yu L, Ma H, Zhang H. Ginsenoside Rg 2 ameliorates myocardial ischemia/reperfusion injury by regulating TAK1 to inhibit necroptosis. Front Cardiovasc Med 2022;9. doi: 10.3389/fcvm.2022.824657.

[29] Ning K, Jiang L, Hu T, Wang X, Liu A, Bao Y. ATP-sensitive potassium channels mediate the cardioprotective effect of Panax notoginseng saponins against myocardial ischaemia-reperfusion injury and inflammatory reaction. BioMed Res Int 2020;2020. doi: 10.1155/2020/3039184.

[30] Ding S, Yang Y, Mei J. Protective effects of L-malate against myocardial ischemia/reperfusion injury in rats. J Evid Based Integr Med 2016;2016. doi: 10.1155/2016/3803657.

[31] Ahmed M, Chowdhury NA, Rahman A, Rahman M, Amin MG, Jannat S, et al. Elevated plasma high sensitivity c-reactive protein (hs-CRP) level is a predictor of periprocedural myocardial injury during percutaneous coronary intervention (PCI). Bangladesh Heart J 2016; 30(1):5-12.

[32] Yang XM, Liu Y, Cui L, Yang X, Liu Y, Tandon N, et al. Platelet P2Y12 blockers confer direct postconditioning-like protection in reperfused rabbit hearts. J Cardiovasc Pharmacol Ther 2013; 18(3):251-262.

[33] Cheng Q, Wang M, Jin R, Li G. Blocking of PI3-kinase beta protects against cerebral ischemia/reperfusion injury by reducing platelet activation and downstream microvascular thrombosis in rats. Sci Rep 2023; 13(1). doi: 10.1038/s41598-023-29235-2.

[34] Yao Y, Zeng Z, Zhao Y, Li T, Liu Y, Chen R. Effect of Shexiang Tongxin dripping pills on coronary microcirculation disorder and cardiac dysfunction in a porcine model of myocardial ischemia-reperfusion injury. Nan Fang Yi Ke Da Xue Xue Bao 2020; 40(6):899-906.

[35] Wang R, Wang M, Zhou J, Ye T, Xie X, Ni D, et al. Shuxuening injection protects against myocardial ischemia-reperfusion injury through reducing oxidative stress, inflammation and thrombosis. Ann Transl Med 2019; 7(20):562-562.

[36] Fan Z, Cai L, Wang S, Wang J, Chen B. Baicalin prevents myocardial ischemia/reperfusion injury through inhibiting ACSL4 mediated ferroptosis. J Pharm Pharm Sci 2021;12. doi: 10.3389/fphar.2021.628988.

[37] Li T, Tan Y, Ouyang S, He J, Liu L. Resveratrol protects against myocardial ischemia-reperfusion injury via attenuating ferroptosis. Gene 2022; 808. doi: 10.1016/j.gene.2021.145968.

[38] El-Meanawy SK, Dooge H, Wexler AC, Kosmach AC, Serban L, Santos EA, et al. Overexpression of a short sulfonylurea splice variant increases cardiac glucose uptake and uncouples mitochondria by regulating ROMK activity. Life 2023; 13(4). doi: 10.3390/life13041015.

[39] Flori L, Montanaro R, Pagnotta E, Ugolini L, Righetti L, Martelli A, et al. Erucin exerts cardioprotective effects on ischemia/reperfusion injury through the modulation of mitoKATP channels. Biomedicines 2023; 11(12). doi: 10.3390/biomedicines11123281.

[40] Prakash P, Misra A, Surin WR, Jain M, Bhatta RS, Pal R, et al. Anti-platelet effects of curcuma oil in experimental models of myocardial ischemia-reperfusion and thrombosis. Thromb Res 2011; 127(2):111-118.

[41] Jia JY, Zang EH, Lv LJ, Li QY, Zhang CH, Xia Y, et al. Flavonoids in myocardial ischemia-reperfusion injury: Therapeutic effects and mechanisms. Chin Herbal Med 2021; 13(1):49-63.

[42] Andreadou I, Bell RM, Bøtker HE, Zuurbier CJ. SGLT 2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models. Biochim Biophys Acta Mol Basis Dis 2020; 1866(7). doi: 10.1016/j.bbadis.2020.165770.